GSK buys autoimmune T cell engager for $300M upfront from Chimagen
As early data show how T cell engagers — originally developed for cancers — can potentially treat a range of autoimmune diseases, GSK is buying its own …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
